MediWound Ltd. Reports Share Acquisitions in 6-K Filing

TL;DR

MediWound bought back some shares, maybe they think it's cheap.

AI Summary

MediWound Ltd. (the "Company") filed a Form 6-K on December 16, 2024, to report recent open market acquisitions of its ordinary shares. The filing indicates the company is submitting its report as a foreign private issuer and will file its annual reports under Form 20-F.

Why It Matters

This filing signals potential insider buying or company-level share repurchases, which can be interpreted as a positive signal about the company's valuation and future prospects.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of share acquisitions and does not contain information about significant financial changes or operational risks.

Key Players & Entities

• MediWound Ltd. (company) — Registrant
• December 2024 (date) — Reporting period
• Form 6-K (document) — Filing type
• Form 20-F (document) — Annual report form

FAQ

Key Financial Figures

• $17.13 — an average purchase price per share was $17.13. These transactions were conducted in a

Filing Documents

• zk2432464.htm (6-K) — 9KB
• 0001178913-24-003986.txt ( ) — 10KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): CONTENTS MediWound Ltd. (the "Company") is filing this Form 6-K to report recent open market acquisitions of its ordinary shares by certain members of its Board of Directors and the Chief Executive Officer. Between December 9 and December 13, 2024, Mr. Nachum (Homi) Shamir, Chairman of the Board, Mr. Ofer Gonen, the Company's Chief Executive Officer, and additional Board members individually purchased ordinary shares of the Company in open market transactions. These purchases amounted to an aggregate of 18,462 ordinary shares at an average purchase price per share was $17.13. These transactions were conducted in adherence to all pertinent requirements outlined in the Company's insider trading policy. The content of this report on Form 6-K, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and August 29, 2024 (Registration Nos. 333-265203 and 333-281843, respectively). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 16, 2024 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR